BridgeBio Pharma
BridgeBio Pharma Logo
About BridgeBio Pharma
BridgeBio Pharma Inc is a commercial-stage biopharmaceutical company focused on discovering, developing, and delivering transformative medicines for patients with genetic diseases and cancers. Its pipeline includes treatments such as Attruby for transthyretin-mediated amyloidosis, low-dose infigratinib for achondroplasia and hypochondroplasia, Encaleret for autosomal dominant hypocalcemia type 1, and BBP-418 for limb-girdle muscular dystrophy type 2I/R9. The company also develops products for mendelian, oncology, and gene therapy diseases, and collaborates with leading research institutions and pharmaceutical companies. BridgeBio Pharma serves patients worldwide.
Address
3160 Porter Drive, Suite 250
Palo Alto, 94304
United States
Year founded
2019
Number of employees
700-800
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Report inaccurate data
Request an update to help us keep the brand up-to-date.
